Mirador Capital Partners LP Boosts Position in 10x Genomics, Inc. (NASDAQ:TXG)

Mirador Capital Partners LP grew its holdings in shares of 10x Genomics, Inc. (NASDAQ:TXG - Free Report) by 39.2% during the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 80,983 shares of the company's stock after buying an additional 22,792 shares during the period. Mirador Capital Partners LP owned 0.07% of 10x Genomics worth $1,163,000 as of its most recent SEC filing.

Several other institutional investors also recently modified their holdings of TXG. JPMorgan Chase & Co. raised its stake in 10x Genomics by 355.0% during the third quarter. JPMorgan Chase & Co. now owns 355,488 shares of the company's stock valued at $8,027,000 after buying an additional 277,355 shares during the last quarter. Lecap Asset Management Ltd. purchased a new position in shares of 10x Genomics in the 3rd quarter worth about $877,000. Geode Capital Management LLC boosted its stake in 10x Genomics by 2.4% in the 3rd quarter. Geode Capital Management LLC now owns 1,815,710 shares of the company's stock worth $41,009,000 after purchasing an additional 42,777 shares in the last quarter. Marshall Wace LLP bought a new position in 10x Genomics in the 2nd quarter worth about $689,000. Finally, Point72 Asset Management L.P. purchased a new stake in 10x Genomics during the 3rd quarter valued at about $27,778,000. 84.68% of the stock is currently owned by institutional investors.

10x Genomics Stock Up 0.7 %

Shares of TXG traded up $0.11 during mid-day trading on Thursday, hitting $15.09. 2,727,993 shares of the company traded hands, compared to its average volume of 2,051,989. The company has a market capitalization of $1.83 billion, a PE ratio of -9.86 and a beta of 1.83. The business has a 50 day moving average of $14.99 and a 200 day moving average of $18.00. 10x Genomics, Inc. has a 1-year low of $12.95 and a 1-year high of $51.22.

10x Genomics (NASDAQ:TXG - Get Free Report) last issued its quarterly earnings results on Tuesday, October 29th. The company reported ($0.30) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.34) by $0.04. 10x Genomics had a negative net margin of 28.93% and a negative return on equity of 25.07%. The business had revenue of $151.65 million for the quarter, compared to analyst estimates of $158.84 million. During the same quarter in the prior year, the business posted ($0.51) EPS. 10x Genomics's revenue for the quarter was down 1.3% compared to the same quarter last year. As a group, research analysts expect that 10x Genomics, Inc. will post -1.43 EPS for the current fiscal year.

Analysts Set New Price Targets

TXG has been the topic of several analyst reports. UBS Group dropped their target price on shares of 10x Genomics from $25.00 to $20.00 and set a "neutral" rating on the stock in a research note on Wednesday, October 30th. Barclays decreased their price target on 10x Genomics from $21.00 to $19.00 and set an "overweight" rating for the company in a research note on Friday, November 1st. Canaccord Genuity Group decreased their target price on 10x Genomics from $32.00 to $20.00 and set a "buy" rating for the company in a research report on Thursday, October 10th. The Goldman Sachs Group decreased their price objective on shares of 10x Genomics from $16.00 to $14.00 and set a "sell" rating for the company in a report on Wednesday, October 30th. Finally, Stephens reiterated an "overweight" rating and set a $30.00 target price on shares of 10x Genomics in a research note on Thursday, October 10th. One research analyst has rated the stock with a sell rating, seven have assigned a hold rating, eight have given a buy rating and one has assigned a strong buy rating to the company's stock. According to data from MarketBeat, the stock has an average rating of "Moderate Buy" and an average target price of $23.86.

About 10x Genomics

10x Genomics, Inc, a life science technology company, develops and sells instruments, consumables, and software for analyzing biological systems in the America, Europe, the Middle East, Africa, China, and the Asia Pacific. The company provides chromium, chromium connect, and chromium controller instruments, microfluidic chips, slides, reagents, and other consumables products.